Business context and reporting period
The filing is Nanophase Technologies Corporation’s Form 10-K for the fiscal year ended December 31, 2011; it is not a filing for “SOLESENCE, INC.” The company develops and manufactures engineered nanomaterials for personal care, coatings, polishing, plastics and other applications. The filing reports annual results, not a separate fourth-quarter summary.
Financial performance and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Total revenue | $9.65 million | $9.46 million |
| Product revenue | $9.32 million | $9.06 million |
| Gross profit / gross margin | $2.33 million / 24.1% | $2.53 million / 26.7% |
| Operating loss | $3.36 million | $4.10 million |
| Net loss | $3.36 million ($0.16 per share) | $4.08 million ($0.19 per share) |
| Cash used in operating activities | $2.92 million | $1.45 million |
| Cash, cash equivalents and investments at year-end | $2.72 million | $5.77 million |
| Total current assets / current liabilities | $5.35 million / $0.82 million | $8.73 million / $2.26 million |
| Debt | No debt outstanding | No line-of-credit balance |
Gross margin declined as higher cerium oxide costs and increased production volume raised cost of revenue. The company remained loss-making and used substantially more operating cash in 2011. It reported no income tax provision.
Material changes versus the prior year
- Revenue grew about 2%; product revenue increased about 3%, largely due to higher sales to the largest polishing customer. Other revenue fell, partly because 2010 included a paid research project.
- Gross profit fell by about $0.20 million, while operating loss narrowed by about $0.74 million. The 2010 operating loss included $0.70 million of agreement-termination charges that did not recur in 2011; lower selling, general and administrative expense also helped.
- Research and development expense rose to $1.74 million from $1.61 million; selling, general and administrative expense declined to $3.95 million from $4.31 million.
- Cash and investments fell by about $3.05 million. Working capital and cerium oxide cost increases contributed to cash use.
- Customer concentration shifted: the top three customers accounted for approximately 54%, 21% and 7% of revenue in 2011, versus 65%, 8% and 7% in 2010.
Outlook, risks and unusual items
- Management expects customer adoption and potential revenue growth in 2012 and beyond, citing new abrasion-resistant additives, polishing opportunities and other developing applications. This is not quantified formal guidance; the timing and commercial viability of opportunities remain uncertain.
- Management believed available cash, operating cash and accessible capital would fund plans through 2012 and into 2013. Planned 2012 capital spending was estimated at $200,000–$500,000 if identified projects proceed; additional financing might not be available on acceptable terms.
- Cerium oxide supply and pricing remain a material risk to polishing operations. Prices had declined from 2011 peaks by early 2012, but remained above mid-2010 levels; long-term supply and cost were uncertain.
- Three customers represented approximately 82% of 2011 revenue. BASF alone accounted for 54%. BASF agreements include conditions that could give BASF rights to technology and production equipment if specified triggers occur. One financial trigger involves negative trailing-12-month earnings together with cash and certain investments below $2 million; year-end liquidity exceeded that threshold by approximately $0.72 million.
- The company voluntarily delisted from Nasdaq and began trading on OTCQB on March 20, 2012 after failing to meet Nasdaq’s minimum bid-price requirement. Management warned that an unsuitable trading venue could hinder access to capital markets.
- The company reported approximately $78 million of tax net operating loss carryforwards, but ownership-change restrictions and expiration dates may limit their use. No legal proceedings were reported. The independent auditor issued an unqualified opinion on the financial statements; management assessed internal control over financial reporting as effective, without an auditor attestation.
Important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Nanophase Technologies Corporation, not SOLESENCE, INC.
- Review the complete BASF supply agreements and the precise financial, operational and insolvency triggers, including potential technology transfer and equipment sale consequences.
- Track cerium oxide availability, pricing, inventory and the company’s ability to pass higher input costs through to customers.
- Assess cash burn, liquidity relative to the $2 million BASF covenant threshold, and the feasibility of management’s funding outlook.
- Monitor customer concentration and evidence that new products and customer-direct sales can generate recurring revenue and improve margins.
- Consider the effects of OTCQB trading on liquidity and future financing access.